Drug Profile
Research programme: inflammation therapy - Amylin Pharmaceuticals/BioSeek
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Amylin Pharmaceuticals
- Developer BioSeek
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation